Literature DB >> 11477353

Pretransplant cachexia and morbid obesity are predictors of increased mortality after heart transplantation.

K Lietz1, R John, E A Burke, J H Ankersmit, J D McCue, Y Naka, M C Oz, D M Mancini, N M Edwards.   

Abstract

BACKGROUND: Extremes in body weight are a relative contraindication to cardiac transplantation.
METHODS: We retrospectively reviewed 474 consecutive adult patients (377 male, 97 female, mean age 50.3+/-12.2 years), who received 444 primary and 30 heart retransplants between January of 1992 and January of 1999. Of these, 68 cachectic (body mass index [BMI]<20 kg/m2), 113 overweight (BMI=>27-30 kg/m2), and 55 morbidly obese (BMI>30 kg/m2) patients were compared with 238 normal-weight recipients (BMI=20-27 kg/m2). We evaluated the influence of pretransplant BMI on morbidity and mortality after cardiac transplantation. Kaplan-Meier survival distribution and Cox proportional hazards model were used for statistical analyses.
RESULTS: Morbidly obese as well as cachectic recipients demonstrated nearly twice the 5-year mortality of normal-weight or overweight recipients (53% vs. 27%, respectively, P=0.001). An increase in mortality was seen at 30 days for morbidly obese and cachectic recipients (12.7% and 17.7%, respectively) versus a 30-day mortality rate of 7.6% in normal-weight recipients. Morbidly obese recipients experienced a shorter time to high-grade acute rejection (P=0.004) as well as an increased annual high-grade rejection frequency when compared with normal-weight recipients (P=0.001). By multivariable analysis, the incidence of transplant-related coronary artery disease (TCAD) was not increased in morbidly obese patients but cachectic patients had a significantly lower incidence of TCAD (P=0.05). Cachectic patients receiving oversized donor hearts had a significantly higher postoperative mortality (P=0.02).
CONCLUSIONS: The risks of cardiac transplantation are increased in both morbidly obese and cachectic patients compared with normal-weight recipients. However, the results of cardiac transplantation in overweight patients is comparable to that in normal-weight patients. Recipient size should be kept in mind while selecting patients and the use of oversized donors in cachectic recipients should be avoided.

Entities:  

Mesh:

Year:  2001        PMID: 11477353     DOI: 10.1097/00007890-200107270-00020

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  11 in total

1.  Impact of Obesity on Ventricular Assist Device Outcomes.

Authors:  Abhishek Jaiswal; Lauren K Truby; Astha Chichra; Rashmi Jain; Leann Myers; Nirav Patel; Veli K Topkara
Journal:  J Card Fail       Date:  2019-10-13       Impact factor: 5.712

2.  Impact of body mass index on adverse events after implantation of left ventricular assist devices: An IMACS registry analysis.

Authors:  Stephen J Forest; Rongbing Xie; James K Kirklin; Jennifer Cowger; Yu Xia; Anne I Dipchand; Cumara Sivathasan; Chris Merry; Lars H Lund; Robert Kormos; Margaret M Hannan; Takeshi Nakatani; Ulrich Jorde; Daniel J Goldstein
Journal:  J Heart Lung Transplant       Date:  2018-06-21       Impact factor: 10.247

Review 3.  Morbid Obesity as a Therapeutic Target for Heart Failure.

Authors:  Chonyang L Albert
Journal:  Curr Treat Options Cardiovasc Med       Date:  2019-09-05

Review 4.  Neuropeptides in the pathophysiology and treatment of cachexia.

Authors:  Stephanie M Krasnow; Daniel L Marks
Journal:  Curr Opin Support Palliat Care       Date:  2010-12       Impact factor: 2.302

5.  Clinical outcomes in overweight heart transplant recipients.

Authors:  Anne Jalowiec; Kathleen L Grady; Connie White-Williams
Journal:  Heart Lung       Date:  2016-04-14       Impact factor: 2.210

6.  The varying effects of obesity and morbid obesity on outcomes following cardiac transplantation.

Authors:  J Nagendran; M D Moore; C M Norris; A Khani-Hanjani; M M Graham; D H Freed; J Nagendran
Journal:  Int J Obes (Lond)       Date:  2016-02-08       Impact factor: 5.095

7.  The impact of sirolimus on hepatitis C recurrence after liver transplantation.

Authors:  Sonal Asthana; Christian Toso; Glenda Meeberg; David L Bigam; Andrew Mason; James Shapiro; Norman M Kneteman
Journal:  Can J Gastroenterol       Date:  2011-01       Impact factor: 3.522

8.  Patient selection for advanced heart failure therapy referral.

Authors:  Alexander C Fanaroff; Adam D DeVore; Robert J Mentz; Mani A Daneshmand; Chetan B Patel
Journal:  Crit Pathw Cardiol       Date:  2014-03

9.  Guidelines for heart transplantation.

Authors:  N de Jonge; J H Kirkels; C Klöpping; J R Lahpor; K Caliskan; A P W M Maat; J Brügemann; M E Erasmus; R J M Klautz; H F Verwey; A Oomen; C H Peels; A E J Golüke; D Nicastia; M A C Koole; A H M M Balk
Journal:  Neth Heart J       Date:  2008       Impact factor: 2.380

10.  Predictors of rehospitalization time during the first year after heart transplant.

Authors:  Anne Jalowiec; Kathleen L Grady; Connie White-Williams
Journal:  Heart Lung       Date:  2008 Sep-Oct       Impact factor: 2.210

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.